First Manhattan’s Genocea Biosciences, Inc. GNCA Stock Holding History

First Manhattan’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,500	Closed	-$3K	–	1739
2022 Q1	$3K	Hold	2,500	–	–	﹤0.01%	1471
2021 Q4	$2K	Hold	2,500	–	–	﹤0.01%	1509
2021 Q3	$4K	Hold	2,500	–	–	﹤0.01%	1470
2021 Q2	$5K	Buy	2,500 +100	+4%	+$241	﹤0.01%	1413
2021 Q1	$6K	Sell	2,400 -1,600	-40%	-$4.74K	﹤0.01%	1327
2020 Q4	$9K	Buy	+4,000	New	+$9.11K	﹤0.01%	1164

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

First Manhattan's GNCA Position: Q2 2022 in Review

First Manhattan sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 2,500 shares — an estimated $3K sold.

First Manhattan first reported a position in GNCA in Q4 2020 and held it in 6 quarters. The position peaked at $9K in Q4 2020. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

First Manhattan reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
First Manhattan sold 2,500 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $3K.
First Manhattan first reported a position in Genocea Biosciences, Inc. in Q4 2020 and held it in 6 quarters.
First Manhattan's Genocea Biosciences, Inc. position peaked at $9K in Q4 2020.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on First Manhattan's 13F filing for Q2 2022, filed 15 Aug 2022.